<DOC>
	<DOC>NCT03071341</DOC>
	<brief_summary>AGT-181 is a fusion protein containing alpha-L-iduronidase that is intended to deliver the enzyme peripherally and to the brain, when administered intravenously. This is a long term safety and tolerability study of AGT-181 in patients with MPS I who completed the previous 26-week study, AGT-181-101. Information on the biological activity of the investigational drug will also be collected.</brief_summary>
	<brief_title>Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis I</mesh_term>
	<criteria>2 years of age or older (and less than 18) Must have been previously enrolled in study AGT181101 Written consent and assent as required Female patients must not be pregnant, willing to utilize appropriate birth control methods and undergo pregnancy testing during the study Refusal to complete all assessments Pregnant or Lactating Received investigational drug within 1 year prior to study enrollment Medical condition or extenuating circumstance that, in the opinion of the investigator, may interfere with study compliance Clinically significant spinal cord compression or evidence of cervical instability (i.e. expected to require intervention during study participation) Has developed clinically relevant hypersensitivity/anaphylactoid reactions to AGT181</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>MPS I; Hurler Syndrome</keyword>
</DOC>